List of Bepreve drug patents

Bepreve is owned by Bausch And Lomb Inc.

Bepreve contains Bepotastine Besilate.

Bepreve has a total of 2 drug patents out of which 0 drug patents have expired.

Bepreve was authorised for market use on 08 September, 2009.

Bepreve is available in solution/drops;ophthalmic dosage forms.

The generics of Bepreve are possible to be released after 13 January, 2025.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8877168 BAUSCH AND LOMB INC Aqueous liquid preparations and light-stabilized aqueous liquid preparations
Jul, 2023

(5 months from now)

US8784789 BAUSCH AND LOMB INC Aqueous liquid preparations and light-stabilized aqueous liquid preparations
Jan, 2025

(1 year, 11 months from now)

Drugs and Companies using BEPOTASTINE BESILATE ingredient

Market Authorisation Date: 08 September, 2009

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of BEPREVE before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in